Hypomagnesemia and proton-pump inhibitors

Author： Famularo Giuseppe   Gasbarrone Laura   Minisola Giovanni  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.12, Iss.5, 2013-09, pp. : 709-716

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacogenomics of proton pump inhibitors

By Furuta Takahisa   Shirai Naohito   Sugimoto Mitsushige   Ohashi Kyoichi   Ishizaki Takashi  

Pharmacogenomics, Vol. 5, Iss. 2, 2004-03 ,pp. : 181-202

Future Medicine

Access to resources Recommend Favorite

Proton-pump inhibitors/solifenacin: Interstitial nephritis (first report with solifenacin) and abnormal renal function: 7 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1164, 2007-01 ,pp. : 20-21

Adis International

Access to resources Recommend Favorite

Formulary Management of Proton Pump Inhibitors

By Byrne M.F.   Murray F.E.  

PharmacoEconomics, Vol. 16, Iss. 3, 1999-09 ,pp. : 225-246

Adis International

Access to resources Recommend Favorite

Pharmacokinetics of Proton Pump Inhibitors in Children

By Litalien Catherine   Théorêt Yves   Faure Christophe  

Clinical Pharmacokinetics, Vol. 44, Iss. 5, 2005-01 ,pp. : 441-466

Adis International

Access to resources Recommend Favorite

Update on the pharmacogenomics of proton pump inhibitors

By Hagymáási Krisztina   Müüllner Katalin   Herszéényi Láászlóó   Tulassay Zsolt  

Pharmacogenomics, Vol. 12, Iss. 6, 2011-06 ,pp. : 873-888

Future Medicine

Access to resources Recommend Favorite